Onderzoek naar optreden van hartfalen na een hartaanval.

Rationale:

Heart failure (HF) is a major medical problem of the Western world, carrying a high morbidity, mortality and economic burden. An ischemic etiology such as an acute myocardial infarction (MI) underlies the development of HF in 70% of all cases. A substantial part of the susceptibility to develop ischemic HF is thought to be largely genetically based. However, genetic variants causing HF have only been identified in some families suffering from non-ischemic HF.



Objective:

The main aim of the current study is to identify novel pathophysiological pathways associated with the development of post-MI HF using genome-wide data and innovative bioinformatics approaches.



Study design:

The study is a multi-center, prospective, longitudinal, observational study.



Study population:

Patients admitted for treatment of a myocardial infarction are considered for inclusion.



Main study parameters/endpoints:

The primary outcome is the incidence of hospitalizations for heart failure. Secondary endpoints include reinfarction, stent thrombosis, arrhythmias, cardiac mortality, all-cause mortality and the combination of all these endpoints.



Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

This is an observational study. Participants will not be exposed to any risks associated with participation to the current study. Participants will not have any advantages or disadvantages by participating in the current study.

The main aim of the current study is to identify novel pathophysiological pathways associated with the development of heart failure after an acute myocardial infarction.

Total follow-up duration is 3-5 years.

N/A